Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3884961 dose-finding study in adults with type 1 Gaucher disease
2022-500281-10-02Phase 2Suspended
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2023
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of LY3884961 in Gaucher disease type 1 (GD1), sponsored by Eli Lilly and Company. Primary endpoint: Incidence and severity of treatment-emergent adverse events and serious adverse events. Started Oct 2023; status: suspended.
02
Drugs
LY3884961
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on 2022-500281-10-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500281-10-02.